Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer

Cytokine

Volumn 64, Issue 2, 2013, Pages 555-563

  Rodríguez Berriguete, Gonzalo ^a   Sánchez Espiridión, Beatriz ^b   Cansino, José R ^c   Olmedilla, Gabriel ^d   Martínez Onsurbe, Pilar ^d   Sánchez Chapado, Manuel ^d   Paniagua, Ricardo ^a   Fraile, Benito ^a   Royuela, Mar ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Biochemical progression; Interleukin 1; Prognosis; Prostate carcinoma; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BIOCHEMICAL PROGRESSION; INTERLEUKIN-1; PROGNOSIS; PROSTATE CARCINOMA; TUMOR NECROSIS FACTOR-Α;

AGED; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885181165     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.09.003     Document Type: Article

References (67)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
3. Swanson G.P., Basler J.W. Prognostic factors for failure after prostatectomy. J Cancer 2010, 2:1-19.
4. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256-269.
5. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
6. Apte R.N., Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?. Immunol Rev 2008, 222:222-241.
7. Bradley J.R., Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001, 20:6482-6491.
8. Lurje G., Hendifar A.E., Schultheis A.M., Pohl A., Husain H., Yang D., et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics 2009, 19:95-102.
9. Kiyohara C., Horiuchi T., Takayama K., Nakanishi Y. IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population. J Thorac Oncol 2010, 5:299-304.
10. Xue H., Lin B., Ni P., Xu H., Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010, 25:1604-1617.
11. Fujiwaki R., Iida K., Nakayama K., Kanasaki H., Hata K., Katabuchi H., et al. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2003, 89:77-83.
12. Rutkowski P., Kaminska J., Kowalska M., Ruka W., Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003, 84:151-159.
13. Dosquet C., Coudert M.C., Lepage E., Cabane J., Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin Cancer Res 1997, 3:2451-2458.
14. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90:2312-2316.
15. Seidemann K., Zimmermann M., Book M., Meyer U., Burkhardt B., Welte K., et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol 2005, 23:8414-8421.
16. Ricote M., Garcia-Tunon I., Bethencourt F., Fraile B., Onsurbe P., Paniagua R., et al. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006, 208:401-407.
17. Ricote M., Royuela M., Garcia-Tunon I., Bethencourt F.R., Paniagua R., Fraile B. Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. J Urol 2003, 170:787-790.
18. Ricote M., Garcia-Tunon I., Bethencourt F.R., Fraile B., Paniagua R., Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004, 100:1388-1396.
19. Nunez C., Cansino J.R., Bethencourt F., Perez-Utrilla M., Fraile B., Martinez-Onsurbe P., et al. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology 2008, 53:166-176.
20. Cheng L., Montironi R., Bostwick D.G., Lopez-Beltran A., Berney D.M. Staging of prostate cancer. Histopathology 2012, 60:87-117.
21. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
22. Oh B.R., Sasaki M., Perinchery G., Ryu S.B., Park Y.I., Carroll P., et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 2000, 163:1584-1587.
23. McCarron S.L., Edwards S., Evans P.R., Gibbs R., Dearnaley D.P., Dowe A., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002, 62:3369-3372.
24. Wu H.C., Chang C.H., Chen H.Y., Tsai F.J., Tsai J.J., Chen W.C. P53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int 2004, 73:41-46.
25. Danforth K.N., Rodriguez C., Hayes R.B., Sakoda L.C., Huang W.Y., Yu K., et al. TNF polymorphisms and prostate cancer risk. Prostate 2008, 68:400-407.
26. Saenz-Lopez P., Carretero R., Cozar J.M., Romero J.M., Canton J., Vilchez J.R., et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008, 8:382.
27. Berhane N., Sobti R.C., Melesse S., Mahdi S.A., Kassu A. Significance of Tumor necrosis factor alpha-308 (G/A) gene polymorphism in the development of prostate cancer. Mol Biol Rep 2012, 39:11125-11130.
28. Lindmark F., Zheng S.L., Wiklund F., Balter K.A., Sun J., Chang B., et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 2005, 93:493-497.
29. Cheng I., Krumroy L.M., Plummer S.J., Casey G., Witte J.S. MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16:1309-1311.
30. Dluzniewski P.J., Wang M.H., Zheng S.L., De Marzo A.M., Drake C.G., Fedor H.L., et al. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2012, 21:1774-1782.
31. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
32. Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999, 1:3-19.
33. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
34. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
35. Kim S.J., Kelly W.K., Fu A., Haines K., Hoffman A., Zheng T., et al. Genome-wide methylation analysis identifies involvement of TNF-alpha mediated cancer pathways in prostate cancer. Cancer Lett 2011, 302:47-53.
36. Nakashima J., Tachibana M., Ueno M., Miyajima A., Baba S., Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 1998, 4:1743-1748.
37. Tse B.W., Scott K.F., Russell P.J. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer 2012, 2012:128965.
38. Sherwood E.R., Pitt Ford T.R., Lee C., Kozlowski J.M. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Mod 1990, 9:44-52.
39. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999, 5:828-831.
40. Knight B., Yeoh G.C., Husk K.L., Ly T., Abraham L.J., Yu C., et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000, 192:1809-1818.
41. Kitakata H., Nemoto-Sasaki Y., Takahashi Y., Kondo T., Mai M., Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002, 62:6682-6687.
42. Komori J., Marusawa H., Machimoto T., Endo Y., Kinoshita K., Kou T., et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008, 47:888-896.
43. Murakami A., Kawabata K., Koshiba T., Gao G., Nakamura Y., Koshimizu K., et al. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells co-cultured with interferon-gamma-stimulated RAW 264.7 cells: the role of tumor necrosis factor-alpha. Cancer Res 2000, 60:6326-6331.
44. Jaiswal M., LaRusso N.F., Shapiro R.A., Billiar T.R., Gores G.J. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001, 120:190-199.
45. Oguma K., Oshima H., Aoki M., Uchio R., Naka K., Nakamura S., et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J 2008, 27:1671-1681.
46. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008, 118:560-570.
47. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
48. Stathopoulos G.T., Kollintza A., Moschos C., Psallidas I., Sherrill T.P., Pitsinos E.N., et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 2007, 67:9825-9834.
49. Leber T.M., Balkwill F.R. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer 1998, 78:724-732.
50. Bates R.C., Mercurio A.M. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003, 14:1790-1800.
51. Kulbe H., Thompson R., Wilson J.L., Robinson S., Hagemann T., Fatah R., et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592.
52. Rodriguez-Berriguete G., Fraile B., Paniagua R., Aller P., Royuela M. Expression of NF-kappaB-related proteins and their modulation during TNF-alpha-provoked apoptosis in prostate cancer cells. Prostate 2012, 72:40-50.
53. Stölting M.N., Ferrari S., Handschin C., Becskei A., Provenzano M., Sulser T., et al. Myoblasts inhibit prostate cancer growth by paracrine secretion of tumor necrosis factor-α. J Urol 2013, 189:1952-1959.
54. Radhakrishnan P., Chachadi V., Lin M.F., Singh R., Kannagi R., Cheng P.W. TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem Biophys Res Commun 2011, 409:436-441.
55. Lü L., Tang D., Wang L., Huang L.Q., Jiang G.S., Xiao X.Y., et al. Gambogic acid inhibits TNF-α-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-κB signaling pathways. Acta Pharmacol Sin 2012, 33:531-541.
56. Song X., Voronov E., Dvorkin T., Fima E., Cagnano E., Benharroch D., et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003, 171:6448-6456.
57. Chirivi R.G., Chiodoni C., Musiani P., Garofalo A., Bernasconi S., Colombo M.P., et al. IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. Int J Cancer 1996, 67:856-863.
58. Bjorkdahl O., Dohlsten M., Sjogren H.O. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Cancer Gene Ther 2000, 7:1365-1374.
59. Chen L.C., Wang L.J., Tsang N.M., Ojcius D.M., Chen C.C., Ouyang C.N., et al. Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med 2012, 4:1276-1293.
60. Krelin Y., Voronov E., Dotan S., Elkabets M., Reich E., Fogel M., et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007, 67:1062-1071.
61. Carmi Y., Rinott G., Dotan S., Elkabets M., Rider P., Voronov E., et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 2011, 186:3462-3471.
62. Steiner G.E., Newman M.E., Paikl D., Stix U., Memaran-Dagda N., Lee C., et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182.
63. Ilvesaro J.M., Merrell M.A., Swain T.M., Davidson J., Zayzafoon M., Harris K.W., et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007, 67:774-781.
64. Hsieh T.C., Chiao J.W. Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett 1995, 95:119-123.
65. Culig Z., Hobisch A., Herold M., Hittmair A., Thurnher M., Eder I.E., et al. Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br J Cancer 1998, 78:1004-1011.
66. Chiao J.W., Hsieh T.C., Xu W., Sklarew R.J., Kancherla R. Development of human prostate cancer cells to neuroendocrine-like cells by interleukin-1. Int J Oncol 1999, 15:1033-1037.
67. Cheng J., Li L., Liu Y., Wang Z., Zhu X., Bai X. Interleukin-1α induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells. Mol Med Rep 2012, 6:955-960.